Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine

NCT05313035 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: SARS-CoV-2 protein subunit recombinant vaccine
BIOLOGICAL: placebo

Sponsor

PT Bio Farma

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]